TY - JOUR AU - Chaudhuri, Aadel A. AU - Chen, Kevin AU - Diehn, Maximilian AU - Loo Jr, Billy W. PY - 2019 TI - Stereotactic ablative radiotherapy for central and ultra-central lung tumors JF - Therapeutic Radiology and Oncology; Vol 3 (May 2019): Therapeutic Radiology and Oncology Y2 - 2019 KW - N2 - Stereotactic ablative radiotherapy (SABR) has emerged as a standard-of-care treatment for patients with early stage non-small cell lung cancer (NSCLC) who are poor surgical candidates. Current evidence supports the consensus that lung SABR with biologically effective dose (BED) ≥100 Gy leads to high local tumor control, and that the treatment is generally well-tolerated when applied to peripheral lung tumors. However, several studies present conflicting evidence for the treatment of central and ultra-central lung tumors, with some showing superb outcomes and others showing concerning rates of morbidity and mortality. Therefore, treatment of central and especially ultra-central lung tumors with SABR remains controversial. In this review, we aim to present the existing evidence for SABR treatment of central and ultra-central lung tumors and delineate the factors that could lead to significant toxicity. UR - https://tro.amegroups.org/article/view/5079